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P-Type Natriuretic Peptide Levels
n Obese Patients With Advanced Heart Failure
amara B. Horwich, MD, Michele A. Hamilton, MD, FACC, Gregg C. Fonarow, MD, FACC
os Angeles, California
OBJECTIVES This study aimed to examine the influence of obesity on the predictive value of the B-type
natriuretic peptide (BNP) assay in heart failure (HF).
BACKGROUND Recent studies show that obesity, or elevated body mass index (BMI), is associated with lower
circulating levels of BNP both in the general population and in patients with HF.
METHODS We analyzed data from 316 systolic HF (left ventricular ejection fraction [LVEF] 40%)
patients [age, 53  13 years; mean LVEF, 24  7%; 48% ischemic] followed up at a
university HF center. Patients were divided into categories of BMI: lean (BMI 25 kg/m2),
overweight (BMI  25 to 29.9 kg/m2), and obese (BMI 30 kg/m2).
RESULTS The BNP levels were significantly lower in overweight and obese compared with lean patients
(p 0.0001); median BNP (interquartile range) for the lean (n 131), overweight (n 99),
and obese (n  86) groups was 747 (272 to 1,300), 380 (143 to 856), and 332 (118 to 617)
pg/ml, respectively. In each BMI category, elevated BNP was significantly associated with
worse symptoms and higher pulmonary capillary wedge pressure. Higher BNP was also a
significant independent predictor of survival independent of BMI. Optimal BNP cutoff for
prediction of death or urgent transplant in lean, overweight, and obese HF patients was 590,
471, and 342 pg/ml, respectively.
CONCLUSIONS Although BNP levels are relatively lower in overweight and obese HF patients, BNP predicts
worse symptoms, impaired hemodynamics, and higher mortality at all levels of BMI. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.050Coll Cardiol 2006;47:85–90) © 2006 by the American College of Cardiology Foundation
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p-type natriuretic peptide (BNP) facilitates the diagnosis of
eart failure (HF) (1) and in patients with pre-existing HF,
NP correlates with HF severity, ventricular filling pres-
ures (2,3), and HF outcomes (4). The BNP levels are
ffected by demographic variables such as age, gender, and
thnicity, and clinical characteristics such as hypertension,
trial fibrillation, and renal function (5–7).
Recent reports suggest that obesity, as indexed by ele-
ated body mass index (BMI), also affects BNP levels, with
ower circulating levels in those with a higher BMI. The
nverse relationship between BNP and BMI has been
bserved in diverse populations, including healthy individ-
als, patients presenting to emergency departments with
yspnea, and chronic HF patients (6,8,9).
Obesity, an increasingly prevalent condition in the U.S.,
ontributes to the development of HF (10). In patients with
stablished HF, overweight and obesity are common, oc-
urring in approximately 30% of patients (11), and thus
urther elucidation of the relationship between BNP and
MI is critical. Our study aimed to further explore the
ssociation between elevated BMI and BNP in advanced
F, focusing on the influence of co-existing factors such as
ender, age, hypertension, and diabetes. We also address a
linically relevant, as yet unanswered question: does the
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ccepted August 1, 2005.resence of obesity affect the prognostic value of BNP in
dvanced HF?
ETHODS
atient population. The study population consisted of 316
onsecutive HF patients seen at a single university medical
enter for HF management and/or heart transplantation
valuation between July 2000 and June 2004. Subjects with
eft ventricular ejection fraction (LVEF) 40%, creatinine
2.5 mg/dl, or a clinical diagnosis of acute coronary
yndrome or myocarditis at time of referral were excluded.
he BNP was measured in all patients within one month of
nitial referral date through the use of an industry-standard
nalytical platform (Triage, Biosite, San Diego, California).
edical record review was approved by the Medical Insti-
utional Review Board of the University of California, Los
ngeles.
tatistical analysis. Patients were divided into three BMI
ategories based on World Health Organization/National
nstitutes of Health guidelines: lean (BMI 25.0 kg/m2),
verweight (BMI 25.0 to 29.9 kg/m2), and obese (BMI
30.0 kg/m2) (12). Differences in baseline characteristics
etween groups were analyzed using independent samples t
est, analysis of variance, chi-square, Kruskal-Wallis, and
ann-Whitney tests, as appropriate. The p values for analysis
f variance test the hypothesis that several means are equal.
ultivariate logistic regression analysis was used to estimate
dds ratios (OR) for low BNP (BNP 100 pg/ml) in
verweight and obese patients. Receiver operator curves for
rediction of one-year outcomes by BNP were generated in
ach BMI category; optimal cutoff points were defined by
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BNP and Obesity in Heart Failure January 3, 2006:85–90aximization of the sum of sensitivity and specificity.
roduct-moment survival estimates were calculated using
he Kaplan-Meier method. Cox regression models esti-
ated the one- and two-year hazard ratios and 95%
onfidence intervals of BNP levels in predicting mortality.
he primary end points analyzed were: 1) all-cause mortal-
ty, with censoring at the time of any heart transplantation,
nd 2) survival free from death or urgent transplantation
status Ia), with censoring at time of non-urgent transplan-
ation (status Ib or II). All statistics were calculated with
tatistical Package for Social Sciences version 12.0 for
indows (SPSS Inc., Chicago, Illinois).
ESULTS
besity and baseline patient characteristics. Mean age of
he cohort was 53  13 years, mean LVEF was 24  7%,
Table 1. Baseline Characteristics of the Cohor
Lean
n  131 (42%)
Age, yrs 54  15
Male, % 70
White, % 63
Black, % 7
NYHA III/IV, % 45/49
Ischemic etiology, % 47
Diabetes, % 19
Hypertension, % 44
Smoking history, % 68
LVEF, % 23  7
LVEDD, mm 65  11
LVEDDI, mm/m2 37  6
Severe MR, % 21
Peak VO2, ml/kg/min 12.7  4
ICD, % 40
VAD, % 5
Laboratory values
Serum sodium, mmol/l 135  5
Creatinine, mg/dl 1.2  0.4
Hemoglobin, g/dl 12.8  1.8
Total cholesterol, mg/dl 151  41
Hemodynamics*
Mean BP, mm Hg 75  13
RA pressure, mm Hg 9  6
PCW, mm Hg 16.3  6.9
Cardiac index, l/min/m2 2.6  0.9
Results are mean  standard deviation for continuous var
recorded after pulmonary artery catheter-guided therapy.
BP  blood pressure; ICD  implantable cardioverter
LVEDDI  left ventricular end diastolic volume index (LVE
Abbreviations and Acronyms
BMI  body mass index
BNP  B-type natriuretic peptide
CI  confidence interval
HF  heart failure
LVEF  left ventricular ejection fraction
OR  odds ratioMR  mitral regurgitation; NYHA  New York Heart Associa
pressure; RA  right atrial; VAD  ventricular assist device; VO2nd 74% of the cohort was male. Baseline characteristics of
he population according to BMI category are shown in
able 1. The HF medications were similar among the three
MI groups, with the exception of slighter higher rates of
eta-blocker and statin usage in overweight and obese
ubjects.
elationship between BMI and BNP levels. Circulating
NP levels were significantly lower in overweight and obese
F patients compared with lean HF patients. Median
interquartile ranges) values for the lean, overweight, and
bese groups were 747 (272 to 1,300), 380 (143 to 856), and
32 (113 to 617) pg/ml, respectively (Fig. 1). The BNP
evels in patients with a very low BMI (20.0 kg/m2)
ompared with patients with a normal BMI (20.0 to 24.9
g/m2) were 839 (77 to 1,300) pg/ml versus 734 (317 to
,300) pg/ml (p  0.40). The proportion of patients with
NP above 1,000 pg/ml was progressively lower with
ncreases in BMI across a broad range (Fig. 2). Further-
ore, the association between high BMI and low BNP was
onsistent in clinically significant subgroups, with the ex-
eption of diabetic patients (Fig. 3).
A multivariate logistic regression analysis was performed to
etermine independent predictors of low BNP (100 pg/ml, n
52), adjusting for age, gender, race, hypertension, diabe-
es, LVEF, coronary artery disease, New York Heart Asso-
ean, Overweight, and Obese Patients
Overweight
 99 (31%)
Obese
n  86 (27%) p Value
53  12 51  11 0.166
76 78 0.33
69 72 0.41
9 6 0.82
52/25 43/39 0.02
53 43 0.43
26 39 0.007
54 74 0.001
70 67 0.93
24  7 25  8 0.09
67  9 68  12 0.173
34  4 31  5 0.0001
11 6 0.02
13.4  5 11.9  3 0.21
47 47 0.16
3 4 0.42
137  4 136  4 0.04
1.3  0.4 1.3  0.4 0.47
13.3  1.7 13.1  1.7 0.18
178  45 169  66 0.001
78  15 84  14 0.001
10  6 9  5 0.59
16.9  6.0 15.3  6.1 0.57
2.8  0.8 2.8  0.8 0.49
and % (n) total for categorical variables. *Hemodynamics
rillator; LVEDD  left ventricular end diastolic volume;
ody surface area); LVEF  left ventricular ejection fraction;t in L
n
iables
-defib
DD/btion functional class; PCW  pulmonary capillary wedge
 oxygen consumption.
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January 3, 2006:85–90 BNP and Obesity in Heart Failureiation functional class, creatinine, and medications (angio-
ensin converting enzyme inhibitor, angiotensin receptor
ntagonist, beta-blocker, and aldosterone antagonist). Obe-
ity was associated with a greater than six-fold increase in
he odds of having low BNP (OR, 6.7; 95% confidence
nterval [CI], 1.2 to 40.4). Per unit increase in BMI, the
dds of having a low BNP increased by 13% (OR, 1.1; 95%
I, 1.0 to 1.3). After excluding underweight patients (BMI
20), higher BMI was still an independent predictor of
ow BNP, with 23% increased odds of low BNP per unit
ncrease in BMI (OR, 1.2; 95% CI, 1.1 to 1.4).
NP, HF severity, and hemodynamics. In each BMI
ategory, higher BNP was associated with more severe
unctional impairment as well as elevated filling pressures
Figs. 4A and 4B).
igure 1. Box plots showing median circulating levels of B-type natriuretic
eptide (BNP) in lean, overweight, and obese heart failure patients. The
ines represent the median, the boxes represent the interquartile range, and
he I bars represent the 5th and 95th percentiles. BMI body mass index.
igure 2. The proportion of patients with B-type natriuretic peptideo
BNP) 1,000 pg/ml by body mass index (BMI). In parentheses: n 
atients with BNP 1,000 pg/ml, n  total patients in BMI subcategory.NP, obesity, and survival. The mean follow-up time was
56 days (15.2 months). There were 93 heart transplanta-
ions (67 urgent, status Ia, and 26 non-urgent, status Ib or
I), 37 deaths, and 6 patients lost to follow-up during the
rst year. Progressive HF death accounted for 20 deaths,
here as 6 were sudden, 2 were secondary to myocardial
nfarction, and 9 were other or unknown. One-year unad-
usted survival estimates in the lean, overweight, and obese
atients were 80%, 93%, and 88%, respectively (p  0.02).
The BNP predicted outcomes independent of BMI. A
NP above the cohort median (452 pg/ml) was associated
ith impaired survival in lean, overweight, and obese
ubjects (Table 2). On multivariate analysis, BNP remained
n independent predictor of one-year mortality in each BMI
ategory (Table 3).
The receiver operator curve analysis to assess BNP as a
redictor of one-year mortality or urgent heart transplanta-
ion showed that the area under the curve was 0.7 in
ach BMI category (Fig. 5A). Any BNP levels above the
eceiver operator curve-determined cut point predicted
arkedly increased all-cause mortality in each BMI cate-
ory (Fig. 5B).
ISCUSSION
n light of the increasing prevalence of both HF and obesity,
nderstanding the relationship between BMI and BNP
evels is integral to the successful diagnosis and management
f HF. This study shows that overweight and obese HF
atients (BMI 25.0 kg/m2) have significantly lower BNP
evels compared with lean HF patients (BMI25.0 kg/m2),
onfirming reports from previous investigators (6,8,9). The
nverse relationship between BMI and BNP in this cohort
as independent of factors known to affect circulating BNP
evels, including age, race, gender, hypertension, renal func-
ion, and HF medications (5–7,9,13,14).
This study adds to the growing body of knowledge
egarding natriuretic peptide levels and obesity (6,8,9).
owever, this is the first study to show that despite
elatively less circulating BNP in HF patients who are
igure 3. B-type natriuretic peptide (BNP) levels (median) in lean,
verweight, and obese patients stratified by gender, diabetes (DM), and
ypertension (HTN).verweight and obese, BNP retains its prognostic capacity
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BNP  B-type natriuretic peptide.
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BNP and Obesity in Heart Failure January 3, 2006:85–90n this cohort. The BNP not only predicted ventricular
lling pressures and functional class, but also correlated with
ortality at each level of BMI.
echanisms of low BNP in obesity. Given the associa-
ion of obesity with multiple cardiovascular risk factors, the
elationship between elevation of BMI and reduction in
NP is counterintuitive. Several potential mechanistic ex-
lanations deserve consideration. It is possible that the low
atriuretic peptide levels in overweight and obese patients
eflect less advanced stages of HF compared with lean
atients. Elevated BMI was associated with improved out-
omes in this cohort and has been reported previously (11).
owever, ventricular filling pressures were no different in
bese and non-obese patients, arguing against differential
entricular wall stretch/stress as an explanation for differ-
ntial BNP production and release in obese and non-obese
F patients.
Cardiac cachexia, a state characterized by weight loss and
eurohumoral/cytokine activation (15,16), is another poten-
ial explanation for a low BMI-high BNP association.
owever, BNP was statistically similar in underweight
BMI 20.0 kg/m2) and normal-weight patients (BMI 
0.0 to 24.9 kg/m2). There is evidence that inflammatory
ytokines such as tumor necrosis factor-alpha, which may
licit release of BNP from cardiomyocytes (17), are less
ctive in states of obesity. However, an initial investigation
ound tumor necrosis factor-alpha and interleukin-6 to be
imilar in obese and non-obese HF patients (8).
Recent evidence suggests that there may be increased
learance of circulating BNP in obesity. Natriuretic peptide
learance receptors are abundant on human adipocytes (18).
dditionally, the vascularity of adipose tissue may allow for
ncreased degradation of BNP by neutral endopeptidase
19). Conversely, it is also possible that overweight and
besity are associated with less robust synthesis and/or
elease of BNP from the myocardium. Decreased N termi-
al pro-BNP and pro-atrial natriuretic peptide have been
ategories Stratified by Median BNP (452 pg/ml)
Lean
n  131
Overweight
n  99
Obese
n  86
21 6 10
35/17 19/8 13/1
3.7% (1/48, 2.1%) 1.8% (1/58, 1.7%) 6.5% (3/52, 5.8%)
30.4% (20/83, 24.1%) 15.7% (5/41, 12.2%) 23.1% (7/34, 20.6%)
0.0004 0.01 0.03
18.1% (8/48, 16.7%) 7.2% (4/58, 6.9%) 19.8 (10/52, 19.2%
60.1% (48/83, 57.8%) 52.7% (21/41, 51.2%) 39.3 (13/34, 38.2%
0.00001 0.00001 0.05
plan-Meier survival analysis. Bottom numbers in parentheses correspond to numberigure 4. B-type natriuretic peptide (BNP) predicts New York Heart
ssociation (NYHA) functional class (A) and pulmonary capillary wedge
ressure (PCW) (B) independent of body mass index (BMI). Median BNPable 2. One-Year Outcomes for the Lean, Overweight, and Obese C
Total Cohort
n  316
eaths, n 37
rgent/elective transplantations, n 67/26
ll-cause mortality, actuarial rates %
(no. deaths/no. subjects in group, %)
BNP  median (452 pg/ml) 3.4% (5/158, 3.2%)
BNP  median (452 pg/ml) 24.3% (32/158, 20.3%)
p value 0.0001
eath or urgent transplantations actuarial rates %
(no. deaths plus no. urgent transplantations/
no. subjects in group, %)
BNP  median (452 pg/ml), % 14.7% (22/158, 13.9%)
BNP  median (452 pg/ml), % 54.1% (82/158, 52.0%)
p value 0.00001
op number displayed corresponds to one-year event rate in percent, as determined by Ka
ived from log-rank test comparing BNP  median vs. BNP  median.
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January 3, 2006:85–90 BNP and Obesity in Heart Failurebserved in obesity (6,20), which may be suggestive of
ecreased natriuretic peptide production.
Alternatively, decreased circulating BNP levels may not
e a consequence of increased body weight or excess
diposity, but rather may be a causative factor in the genotype
r phenotype that leads to development of obesity. Both ANP
nd BNP are now recognized to be involved in fat metabolism
s stimulators of lipolysis in adipose tissue (21).
tudy limitations. We acknowledge potential limitations
o our study. Our cohort is a selected population with
dvanced HF referred to a tertiary center for disease
anagement and transplantation evaluation. The number of
vents per BMI category was relatively low. The upper limit
f detectable BNP increased from 1,300 to 5,000 pg/ml
uring the study period, although this adjustment likely
ffected all BMI categories to a similar extent. Both BMI
nd BNP may not have been assessed on the same day,
able 3. B-Type Natriuretic Peptide (BNP) as a Determinant of
dvanced Heart Failure
Lean
n  131
ll-cause mortality
Age- and gender-adjusted, HR (95% CI) 5.7 (2.7–11.8), p  0
Multivariate, HR (95% CI) 4.2 (1.7–10.3), p  0
eath or urgent-status transplantation
Age- and gender-adjusted, HR (95% CI) 3.1 (2.1–4.5), p  0.0
Multivariate, HR (95% CI) 3.3 (1.8–5.9), p  0.0
ultivariate analysis is adjusted for gender, age, LVEF, HF etiology, NYHA class,
CI  confidence interval; HR  hazard ratio per 1 standard deviation increase iubgroups. Arrows indicate best cutoff B-type natriuretic peptide (BNP). (B) Sur
evel for each category of body mass index. p values, log rank test. AUC  arelthough maximal delay was one month. We do not we have
ata on weight loss or measures of percent body fat, and also
e did not measure additional neurohormones, cytokines,
r adipokines for correlation with BNP or BMI.
ONCLUSIONS
n this advanced systolic HF cohort, overweight and obese
atients had significantly lower circulating BNP levels
ompared with lean patients, and this relationship was
ndependent of demographics, medications, or severity of
F. Despite the dampening of BNP levels in overweight
nd obese HF patients, BNP retained its prognostic capac-
ty in this population, correlating not only with HF severity
nd hemodynamic status, but also predicting survival. These
ata suggest that the BNP assay is a useful tool for the
anagement of chronic systolic heart failure at all levels of
-Year Mortality in Lean, Overweight, and Obese Patients With
Overweight
n  99
Obese
n  86
3.9 (1.0–15.3), p  0.06 3.9 (1.4–10.4), p  0.009
16.2 (1.25–211.0), p  0.03 9.5 (1.5–58.4), p  0.02
4.5 (2.5–7.9), p  0.02 2.2 (1.3–3.8), p  0.005
5.4 (1.9–15.3), p  0.002 11.5 (2.6–50.2), p  0.001
ine, and hypertension.
NP; other abbreviations as in Table 1.igure 5. (A) Receiver-operator curves for prediction of death or urgent heart transplantation at one-year follow-up in lean, overweight, and obeseOne
.0001
.002
001
001vival curves using the receiver-operator curve-determined best cutoff BNP
a under the curve.
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BNP and Obesity in Heart Failure January 3, 2006:85–90MI, although increased risk may be seen at relatively lower
evels of BNP in the obese.
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